Investors Business Daily recently posted an article about “Finding the best biotech companies to invest in”. The article goes on to say that investing in this field is tricky, clinical plans don’t always come to fruition, and biotech stocks can often suffer at the hands of regulatory decisions from the Food and Drug Administration.
The article discusses Corcept Therapeutics (NASDAQ: CORT) which was ranked 10th out of the 150th fastest-growing stocks at the time with an average annual growth rate of 341%. CORT, over the past 12 months, has traded basically flat.
The article also discusses Vertex Pharmaceuticals (NASDAQ: VRTX) and how on MarketSmith’s list of fastest-growing stocks it ranks no. 19, but since the writing of that article, VRTX has traded basically flat, even considering its partnership with Crispr Therapeutics (NASDAQ: CRSP).
Lastly the article discussed Alexion Pharmaceuticals (NASDAQ: ALXN), the company that makes Soliris, while allowing Amgen (NASDAQ: AMGN) to launch a biosimilar copycat. Since the article was published, ALXN is down about 10%.
This is not to say that biotech’s are no longer a good investment. They are for the long term, if you buy quality.
But if you’re looking to deploy a bit of risk capital in the space, you have to find a niche.
One high growth area are companies addressing the obesity epidemic with diabetic nutrition or medical foods products.
Take a look at Glucose Health, Inc. (OTC Pink: GLUC). Glucose Health manufacturers nutritional beverages for diabetic consumers under the registered trademark GLUCODOWN®.
Glucose Health, Inc. is an under-the-radar company whose GLUCODOWN® products are found in major national pharmacy chains including Walmart (NYSE: WMT), CVS Health (NYSE: CVS) and even online at Amazon.com (NASDAQ: AMZN) yet is still trading below a $20 million valuation.
The Company’s flagship product GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain glucose (blood sugar) levels in a normal healthy range.
Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.
What are the revenues of this company going to look like when the latest Glucose Health, Inc. numbers are reported for Q3 and Q4?
Over the past 12 months, GLUC stock has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetic nutrition/medical foods space and should be on everybody’s watch list.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.